---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-007673"
form_type: "8-K"
ticker: "TXG"
cik: "0001770787"
company_name: "10x Genomics, Inc."
filed_at: "2026-02-12T23:59:59+00:00"
generated_at: "2026-05-16T03:05:22.117460+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# 10x Genomics Q4 revenue $166M (+1% YoY); FY26 guidance $600-625M

## Summary
- Q4 2025 revenue $166.0M (+1% YoY); FY25 $642.8M (+5%), ex-settlements $598.7M (-2%).
- Q4 net loss $16.3M vs $49.0M loss YoY; FY25 net loss $43.5M vs $182.6M loss YoY.
- Operating expenses down 18% Q4 and 17% FY; gross margin 68% Q4 and 69% FY.
- FY2026 revenue guidance $600-625M (0-4% growth ex-2025 settlements).
- Cash and equivalents $523.4M at year-end, up $130M vs prior year.

## SEC filing metadata
- accession: 0001628280-26-007673
- form_type: 8-K
- ticker: TXG
- cik: 0001770787
- company_name: 10x Genomics, Inc.
- filed_at: 2026-02-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770787/000162828026007673/0001628280-26-007673-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770787/000162828026007673/txg-20260212.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-007673
- JSON: https://secwatch.observer/filing/0001628280-26-007673.json
- Plain text: https://secwatch.observer/filing/0001628280-26-007673.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.